|
1.
|
J FerlayDM ParkinE
Steliarova-FoucherEstimates of cancer incidence and mortality in
Europe in 2008Eur J
Cancer46765781201010.1016/j.ejca.2009.12.01420116997
|
|
2.
|
CR JamesJE QuinnPB MullanPG JohnstonDP
HarkinBRCA1, a potential predictive biomarker in the treatment of
breast
cancerOncologist12142150200710.1634/theoncologist.12-2-14217296808
|
|
3.
|
J XuB WangY ZhangR LiY WangS ZhangClinical
implications for BRCA gene mutation in breast cancerMol Biol
Rep3930973102201210.1007/s11033-011-1073-y21691706
|
|
4.
|
HT LynchE SilvaC SnyderJF LynchHereditary
breast cancer: part I. Diagnosing hereditary breast cancer
syndromesBreast
J14313200810.1111/j.1524-4741.2007.00515.x18086272
|
|
5.
|
D ThompsonDF EastonBreast Cancer Linkage
ConsortiumCancer incidence in BRCA1 mutation carriersJ Natl Cancer
Inst9413581365200210.1093/jnci/94.18.135812237281
|
|
6.
|
L KadouriD BercovichA ElimelechA novel
BRCA-1 mutation in Arab kindred from east Jerusalem with breast and
ovarian cancerBMC Cancer714200710.1186/1471-2407-7-1417233897
|
|
7.
|
N MavaddatAC AntoniouDF EastonM
Garcia-ClosasGenetic susceptibility to breast cancerMol
Oncol4174191201010.1016/j.molonc.2010.04.011
|
|
8.
|
C KoumpisC DimitrakakisA
AntsaklisPrevalence of BRCA1 and BRCA2 mutations in unselected
breast cancer patients from GreeceHered Cancer Clin
Pract910201110.1186/1897-4287-9-1022085629
|
|
9.
|
KA MetcalfeJL SempleSA NarodTime to
reconsider subcutaneous mastectomy for breast-cancer
prevention?Lancet
Oncol6431434200510.1016/S1470-2045(05)70210-215925821
|
|
10.
|
V StegelM KrajcJ ZgajnarThe occurrence of
germline BRCA1 and BRCA2 sequence alterations in Slovenian
populationBMC Med Genet129201110.1186/1471-2350-12-921232165
|
|
11.
|
ME RobsonCD StormJ WeitzelDS WollinsK
OffitAmerican Society of Clinical OncologyAmerican Society of
Clinical Oncology policy statement update: genetic and genomic
testing for cancer susceptibilityJ Clin
Oncol28893901201010.1200/JCO.2009.27.066020065170
|
|
12.
|
R RoyJ ChunSN PowellBRCA1 and BRCA2:
different roles in a common pathway of genome protectionNat Rev
Cancer126878201210.1038/nrc318122193408
|
|
13.
|
N TungY WangLC CollinsEstrogen receptor
positive breast cancers in BRCA1 mutation carriers: clinical risk
factors and pathologic featuresBreast Cancer
Res12R12201010.1186/bcr247820149218
|
|
14.
|
P RadiceS De SummaL CalecaS
TommasiUnclassified variants in BRCA genes: guidelines for
interpretationAnn Oncol22Suppl
1i18i23201110.1093/annonc/mdq66121285146
|
|
15.
|
A BorgRW HaileKE MaloneCharacterization of
BRCA1 and BRCA2 deleterious mutations and variants of unknown
clinical significance in unilateral and bilateral breast cancer:
the WECARE studyHum
Mutat31E1200E1240201010.1002/humu.2120220104584
|
|
16.
|
MA FlemingJD PotterCJ RamirezGK
OstranderEA OstranderUnderstanding missense mutations in the BRCA1
gene: an evolutionary approachProc Natl Acad Sci
USA10011511156200310.1073/pnas.023728510012531920
|
|
17.
|
Q ZhongTG BoyerPL ChenWH LeeDeficient
nonhomologous end-joining activity in cell-free extracts from
Brca1-null fibroblastsCancer Res6239663970200212124328
|
|
18.
|
SA GaytherJ MangionP RussellVariation of
risks of breast and ovarian cancer associated with different
germline mutations of the BRCA2 geneNat
Genet15103105199710.1038/ng0197-1038988179
|
|
19.
|
D ThompsonD EastonVariation in cancer
risks, by mutation position, in BRCA2 mutation carriersAm J Hum
Genet68410419200110.1086/31818111170890
|
|
20.
|
U HamannX LiuS LangeHU UlmerA BennerRJ
ScottContribution of BRCA2 germline mutations to hereditary
breast/ovarian cancer in GermanyJ Med
Genet39E12200210.1136/jmg.39.3.e1211897832
|
|
21.
|
A MoranC O’HaraS KhanRisk of cancer other
than breast or ovarian in individuals with BRCA1 and BRCA2
mutationsFam
Cancer11235242201210.1007/s10689-011-9506-222187320
|
|
22.
|
L JaraS AmpueroE SantibanezBRCA1 and BRCA2
mutations in a South American populationCancer Genet
Cytogenet1663645200610.1016/j.cancergencyto.2005.08.01916616110
|
|
23.
|
E RajendraAR VenkitaramanTwo modules in
the BRC repeats of BRCA2 mediate structural and functional
interactions with the RAD51 recombinaseNucleic Acids
Res388296201010.1093/nar/gkp87319875419
|
|
24.
|
MK ShivjiSR MukundE RajendraThe BRC
repeats of human BRCA2 differentially regulate RAD51 binding on
single-versus double-stranded DNA to stimulate strand exchangeProc
Natl Acad Sci
USA1061325413259200910.1073/pnas.090620810619628690
|
|
25.
|
RB JensenA CarreiraSC
KowalczykowskiPurified human BRCA2 stimulates RAD51-mediated
recombinationNature467678683201010.1038/nature0939920729832
|
|
26.
|
JD O’DonnellRJ LingerPA KrukBRCA1 185delAG
mutant protein, BRAt, up-regulates maspin in ovarian epithelial
cellsGynecol Oncol1162622682010
|
|
27.
|
TA KingW LiE BrogiHeterogenic loss of the
wild-type BRCA allele in human breast tumorigenesisAnn Surg
Oncol1425102518200710.1245/s10434-007-9372-117597348
|
|
28.
|
CH StreuliMaspin is a tumour suppressor
that inhibits breast cancer tumour metastasis in vivoBreast Cancer
Res4137140200210.1186/bcr43712100737
|
|
29.
|
N JiangY MengS ZhangE Mensah-OsmanS
ShengMaspin sensitizes breast carcinoma cells to induced
apoptosisOncogene2140894098200210.1038/sj.onc.120550712037665
|
|
30.
|
A KwongEK NgEY TangA novel de novo BRCA1
mutation in a Chinese woman with early onset breast cancerFam
Cancer10233237201110.1007/s10689-011-9429-y21404118
|
|
31.
|
T WagnerD Stoppa-LyonnetE
FleischmannDenaturing high-performance liquid chromatography
detects reliably BRCA1 and BRCA2
mutationsGenomics62369376199910.1006/geno.1999.602610644434
|
|
32.
|
S CaputoL BenboudjemaO SinilnikovaE
RouleauC BeroudR LidereauDescription and analysis of genetic
variants in French hereditary breast and ovarian cancer families
recorded in the UMD-BRCA1/BRCA2 databasesNucleic Acids
Res40D992D1002201210.1093/nar/gkr116022144684
|
|
33.
|
SA JanezicA ZiogasLM KrumroyGermline BRCA1
alterations in a population-based series of ovarian cancer casesHum
Mol Genet8889897199910.1093/hmg/8.5.88910196379
|
|
34.
|
A MusolinoM MichiaraMA BellaMolecular
profile and clinical variables in BRCA1-positive breast cancers. A
population-based studyTumori91505512200516457150
|
|
35.
|
B GorskiA JakubowskaT HuzarskiA high
proportion of founder BRCA1 mutations in Polish breast cancer
familiesInt J Cancer110683686200410.1002/ijc.2016215146557
|
|
36.
|
J SalgadoC GutierrezC GilM RoblesJ
Garcia-FoncillasComparative disease pattern of a patient with a
novel BRCA2 truncation and knockout models for BRCA2Breast Cancer
Res Treat123291293201010.1007/s10549-010-0776-420151322
|
|
37.
|
TS FrankSA ManleyOI OlopadeSequence
analysis of BRCA1 and BRCA2: correlation of mutations with family
history and ovarian cancer riskJ Clin
Oncol162417242519989667259
|
|
38.
|
MA AdankH SegersSE van MilFanconi anemia
gene mutations are not involved in sporadic Wilms tumorPediatr
Blood Cancer55742744201010.1002/pbc.2258820589654
|
|
39.
|
NG HowlettT TaniguchiS OlsonBiallelic
inactivation of BRCA2 in Fanconi
anemiaScience297606609200210.1126/science.107383412065746
|
|
40.
|
BP AlterPS RosenbergLC BrodyClinical and
molecular features associated with biallelic mutations in
FANCD1/BRCA2J Med Genet4419200710.1136/jmg.2006.04325716825431
|
|
41.
|
ZL MaMZ CaoWF LiAnalysis of BRCA2 gene
mutations among familial and/or early-onset breast cancer patients
in eastern Shandong of ChinaZhonghua Yi Xue Yi Chuan Xue Za
Zhi251951982008(In Chinese).
|
|
42.
|
JJ van HarsselCE van RoozendaalY
DetischEfficiency of BRCAPRO and Myriad II mutation probability
thresholds versus cancer history criteria alone for BRCA1/2
mutation detectionFam Cancer9193201201019949876
|
|
43.
|
V Caux-MoncoutierL CasteraC TirapoEMMA, a
cost- and time-effective diagnostic method for simultaneous
detection of point mutations and large-scale genomic
rearrangements: application to BRCA1 and BRCA2 in 1,525 patientsHum
Mutat32325334201110.1002/humu.21414
|
|
44.
|
Z Kote-JaraiD LeongamornlertE
SaundersBRCA2 is a moderate penetrance gene contributing to
young-onset prostate cancer: implications for genetic testing in
prostate cancer patientsBr J
Cancer10512301234201110.1038/bjc.2011.38321952622
|
|
45.
|
CS SinclairC AdemA NaderiTBX2 is
preferentially amplified in BRCA1- and BRCA2-related breast
tumorsCancer Res6235873591200212097257
|
|
46.
|
C AdemC ReynoldsCL SoderbergPathologic
characteristics of breast parenchyma in patients with hereditary
breast carcinoma, including BRCA1 and BRCA2 mutation
carriersCancer97111200310.1002/cncr.1104812491499
|
|
47.
|
AH van der HoutAM van den OuwelandRB van
der LuijtA DGGE system for comprehensive mutation screening of
BRCA1 and BRCA2: application in a Dutch cancer clinic settingHum
Mutat27654666200616683254
|
|
48.
|
BB HermsenPJ van DiestJ BerkhofLow
prevalence of (pre) malignant lesions in the breast and high
prevalence in the ovary and Fallopian tube in women at hereditary
high risk of breast and ovarian cancerInt J
Cancer11914121418200610.1002/ijc.2198816615107
|
|
49.
|
A RomanoPJ LindseyDC FischerTwo
functionally relevant polymorphisms in the human progesterone
receptor gene (+331 G/A and progins) and the predisposition for
breast and/or ovarian cancerGynecol Oncol101287295200616360811
|
|
50.
|
S LevanatV MusaniML CvokThree novel
BRCA1/BRCA2 mutations in breast/ovarian cancer families in
CroatiaGene498169176201210.1016/j.gene.2012.02.01022366370
|
|
51.
|
WK HollomanUnraveling the mechanism of
BRCA2 in homologous recombinationNat Struct Mol
Biol18748754201110.1038/nsmb.209621731065
|
|
52.
|
H YangPD JeffreyJ MillerBRCA2 function in
DNA binding and recombination from a BRCA2-DSS1-ssDNA
structureScience29718371848200210.1126/science.297.5588.183712228710
|
|
53.
|
N SiaudMA BarberaA EgashiraPlasticity of
BRCA2 function in homologous recombination: genetic interactions of
the PALB2 and DNA binding domainsPLoS
Genet7e1002409201110.1371/journal.pgen.100240922194698
|
|
54.
|
PC FongTA YapDS BossPoly(ADP)-ribose
polymerase inhibition: frequent durable responses in BRCA carrier
ovarian cancer correlating with platinum-free intervalJ Clin
Oncol2825122519201010.1200/JCO.2009.26.9589
|
|
55.
|
AB SpurdleSR LakhaniS HealeyClinical
classification of BRCA1 and BRCA2 DNA sequence variants: the value
of cytokeratin profiles and evolutionary analysis - a report from
the kConFab InvestigatorsJ Clin
Oncol2616571663200810.1200/JCO.2007.13.277918375895
|
|
56.
|
HA RischJR McLaughlinDE ColePopulation
BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a
kin-cohort study in Ontario, CanadaJ Natl Cancer
Inst9816941706200610.1093/jnci/djj46517148771
|
